Regulatory Authority Actions

The agency found insanity conditions and CGMP violations at Pharmedica USA, LLC’s Phoenix facility during an inspection.

The two draft guidance documents provide recommendations for the approval of pediatric drugs, biologics, and vaccines under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act.

In a brief, the Federal Trade Commission cited concerns about the acquisition resulting in an increased monopoly on Amgen’s newly acquired thyroid eye disease and chronic refractory gout treatments.

Congress have initiated a range of legislative proposals to further manage PBMs and the pharma market.

Further, the guidance is to provide information on compliance with applicable regulatory requirements and recommendations.

GSK’s Alexvy vaccine is the first to receive FDA approval for respiratory syncytial virus.

FDA’s Division of Applied Regulatory Science’s (DARS) computational toxicology and pharmacology research has been focused on the development of highly curated data sets and QSAR models for endpoints of regulatory interest.

The recent revision is intended to provide guidance on QRM principles and tools that can be used for different aspects of pharmaceutical quality.

This specific guidance refers to a DCT as a clinical trial where some or all the trial-related activities occur at locations other than traditional clinical trial sites.

FDA is encouraging sponsors to conduct studies and file applications for full approval of products authorized by Emergency Use Authorizations.

The Supreme Court’s action leaves open the prospect of further rulings that could undermine FDA’s approval process.

SAB Biotherapeutics has received both breakthrough and fast track designations from FDA for its lead antibody drug candidate for treating influenza.

Jaeger notes that the program is focused on addressing specific scientific questions that will produce immediate impacts on how CDER and FDA make drug approval decisions.

Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.

The decision was issued in a joint statement by the FDA Commissioner and Chief Scientist, and effective on April 11.

A document signed by members of more than 400 companies and investment firms decries the decision made by a federal judge concerning mifepristone, a medication used in abortions.

Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?

The agency is dealing with high demand for staff because of a surge in the development of cell and gene therapies.

FDA aims to address mounting criticisms of its accelerated approval pathway.

FDA has spurred investment to create and develop 600 therapies.

FDA has approved Evkeeza for young children with homozygous familial hypercholesterolemia.

Narcan, from Emergent Solutions, will be the first naloxone product permitted for use without prescription by FDA.

A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.

The recent document will guide the use of DHT-derived data in regulatory decision-making for drugs and biological products.

27 drugs within Medicare will face penalties for having their prices raised faster than the rate of inflation.